Opinion on R&D in Europe

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

GlaxoSmithKline: smoke blows both ways

A new study suggests that without physician support, OTC nicotine replacement drugs may be useless. This is interesting reading for GSK, which is the biggest producer of anti-smoking drugs. The news should boost prescription-only Zyban, but GSK may have to invest in physician support to maintain sales of NRT drugs Nicorette and NicoDerm.

Published By Datamonitor
12 Sep 2002
CommentWire
CommentWire

Genentech: Avastin on track for 2004 launch

Genentech looks set to add Avastin to its growing number of successfully marketed innovative products, judging by the announcement of positive phase III clinical trial results in colorectal cancer patients. The results pave the way for Avastin to be launched in late 2004, making it the first angiogenesis inhibitor available for the treatment of colorectal cancer.

Published By Datamonitor
20 May 2003
CommentWire
CommentWire

etrials/Eclipse: taking clinical EDC to Europe

US clinical trial data management firm etrials hopes that its deal with Irish-based contract research organization Eclipse will allow it to expand into Europe. It looks set to pay off: electronic trials should soon take off in Europe, and Eclipse has a strong multinational sales presence.

Published By Datamonitor
30 May 2002
CommentWire
CommentWire

Elan: trying to save a would-be blockbuster

The temporary suspension, on reports of worrying side effects, rocked shareholder confidence in Ireland's largest public company. Investors fear that one of Elan's two lead compounds may never generate revenue. The company may be able to save AN-1792, in which case it could still be a blockbuster drug - but the risks attached are high.

Published By Datamonitor
23 Jan 2002
CommentWire
CommentWire

Eczema: friendly food bugs can help

According to a new study, giving probiotics to babies while they are being weaned may reduce their chances of developing allergic conditions such as eczema. Although further research is required, probiotics may have a significant role to play in several conditions caused by allergic inflammation. This represents both a threat and an opportunity to pharma companies.

Published By Datamonitor
25 Jun 2002
CommentWire
CommentWire

Diesel cars: sales on the up

The technological advances made in diesel engines has fuelled a steady increase in their sales across Europe. With the diesel models of some manufacturers already outselling petrol models, the only way to maintain current diesel growth rates will be if other companies commit to more specialist diesel development.<BR />

Published By Datamonitor
19 May 2003
CommentWire
CommentWire

Diagene: new treatment guidelines should boost sales

Published By Datamonitor
24 Sep 2001
ResearchWire
ResearchWire

Diabetes: Novo Nordisk goes for broke

Published By Datamonitor
06 Nov 2001
CommentWire
CommentWire

Diabetes: mice cured, now trying people

Although much further research is required, it could be viable to develop a genetic therapy for humans based on this discovery. While this could pose a threat to pharma companies in the $11.5 billion diabetes market, these firms are also in a strong position to exploit the new discoveries.

Published By Datamonitor
14 May 2002
CommentWire
CommentWire

Diabetes: maternal smoking is a risk factor

The data shows that maternal smoking during pregnancy is a risk factor for the development of early onset diabetes in offspring. Independently, cigarette smoking as a young adult can also increase the risk of subsequent diabetes. Given the huge economic impact of diabetes, it's clear that governments must do more to deter people from smoking.

Published By Datamonitor
08 Jan 2002

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | » »|

No help is available.